Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Imunon ( (IMNN) ) is now available.
On June 13, 2025, Imunon, Inc. terminated its consulting agreement with Monomoy Advisors, LLC, ending David Gaiero’s role as interim Chief Financial Officer. Subsequently, Kimberly Graper was appointed as the new interim Chief Financial Officer, bringing extensive experience from her previous roles at various companies, including F2G Inc. and Timber Pharmaceuticals, Inc.
The most recent analyst rating on (IMNN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
Imunon, Inc. operates in the financial advisory services industry, focusing on providing financial management and consulting services.
Average Trading Volume: 10,877,251
Technical Sentiment Signal: Buy
Current Market Cap: $29.12M
See more data about IMNN stock on TipRanks’ Stock Analysis page.